Crinetics Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces September 2022 inducement grants: the stock options were granted as inducements material to 13 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference


Crinetics Pharmaceuticals management will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022

New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly


Two-year data from Advance OLE acromegaly study shows maintenance of IGF-1 and preference for paltusotine over injected SRLs

New Long-Term Safety and Efficacy Data for Paltusotine to be Presented at CBEM


New safety and efficacy data from a two-year interim analysis from the ACROBAT Advance study will be presented at the 35th Brazilian Congress of Endocrinology and Metabolism

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update


Crinetics reported financial results for the second quarter ended June 30, 2022 and provided an update on paltusotine's Phase 3 program in acromegaly and Phase 2 in carcinoid syndrome, as well as plans to advance CRN04894 and CRN04777.